Evoke Pharma (EVOK) Misses Q3 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Evoke Pharma Reports Third Quarter 2017 Results and Highlights
November 14, 2017 4:05 PM ESTAnnounced positive topline results from comparative exposure pharmacokinetic (PK) trial for Gimoti505(b)(2) New Drug Application (NDA) submission on track for Q1 2018 filingPartnered with the Patheon division of Thermo Fisher Scientific Inc. as a commercial manufacturing partner for Gimoti$10.4M in cash and extended estimated cash runway now through June 2018
SOLANA BEACH, Calif., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the third quarter ended September... More
